EU Trails U.S. on Biotech R&D Spending, Capability is Building

Europe needs to step up its investment in biotech R&D and establish supportive regulatory policies if it is to keep pace with the U.S. in the biotech sector, says Stephan Tanda, board member for DSM and chairman of industry biotech association EuropaBio. Total biotech R&D spending by publicly traded companies in the U.S. in 2009-2010 was $17.6 billion. This compares with €3.4 billion ($4.7 billion) in Europe during the same period. Tanda made his comments speaking earlier today at The European Forum for Industrial Biotechnology (EFIB) in Amsterdam...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers